Together with previous findings, this suggests that exploring Neat1 as a novel diagnostic biomarker in body fluids (such as cerebrospinal fluid or blood), as well as potential therapeutic intervention target for ALS, may offer promising insights. This evidence concerns the gene NEAT1 and amyotrophic lateral sclerosis.